Trimph

Tetratherix is an Australian listed regenerative medicine and medical technology company developing biomaterial-based products built on its Tetramatrix platform, a temperature-responsive injectable fluid matrix that forms an implantable scaffold in the body. The business originated as Trimph and later rebranded to Tetratherix, with the platform being applied across bone regeneration, tissue spacing, tissue healing, and more recently precision medicine drug delivery. Its lead franchises include Tegenix for dental bone regeneration, TegenEOS for orthopedic bone repair, Tutelix for oncology tissue spacing, Optelex for ophthalmic applications, and TetraDerm for scar reduction. The company manufactures advanced biomaterial products in-house and positions itself as a platform-based medtech with applications spanning multiple specialties. Tetratherix completed an IPO on the ASX in June 2025 and has guided toward U.S. regulatory approvals for bone regeneration products in 2026.